Company profile
ORGANOGENESIS HOLDINGS INC.
NASDAQ:ORGOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| GINTUIT | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06000410 | phase3 | completed | 2023-09-06 | 2025-08-15 | Organogenesis | A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
| NCT04636229 | phase3 | completed | 2020-12-14 | 2023-07-30 | Organogenesis | Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
| NCT01929954 | phase1_2 | terminated | 2013-07-01 | 2015-03-01 | Organogenesis | Safety Study of Gintuit™ in Subjects Requiring Socket Grafting |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125400 | 2012-03-09 | BLA | ORGANOGENESIS, INC. | |||||
Loading… | ||||||||